Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein
-
Published:2022-08-17
Issue:1
Volume:13
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Castro Julia T., Azevedo Patrick, Fumagalli Marcílio J.ORCID, Hojo-Souza Natalia S., Salazar Natalia, Almeida Gregório G., Oliveira Livia I., Faustino Lídia, Antonelli Lis R.ORCID, Marçal Tomas G., Augusto Marconi, Valiate Bruno, Fiorini Alex, Rattis Bruna, Ramos Simone G., Piccin MarielaORCID, Nonato Osvaldo Campos, Benevides Luciana, Magalhães Rubens, Cassaro Bruno, Burle Gabriela, Doro Daniel, Kalil Jorge, Durigon Edson, Salazar Andrés, Caballero Otávia, Santiago HeltonORCID, Machado Alexandre, Silva João S., da Fonseca Flávio, Fernandes Ana Paula, Teixeira Santuza R., Gazzinelli Ricardo T.ORCID
Abstract
AbstractBoth T cells and B cells have been shown to be generated after infection with SARS-CoV-2 yet protocols or experimental models to study one or the other are less common. Here, we generate a chimeric protein (SpiN) that comprises the receptor binding domain (RBD) from Spike (S) and the nucleocapsid (N) antigens from SARS-CoV-2. Memory CD4+ and CD8+ T cells specific for SpiN could be detected in the blood of both individuals vaccinated with Coronavac SARS-CoV-2 vaccine and COVID-19 convalescent donors. In mice, SpiN elicited a strong IFN-γ response by T cells and high levels of antibodies to the inactivated virus, but not detectable neutralizing antibodies (nAbs). Importantly, immunization of Syrian hamsters and the human Angiotensin Convertase Enzyme-2-transgenic (K18-ACE-2) mice with Poly ICLC-adjuvanted SpiN promotes robust resistance to the wild type SARS-CoV-2, as indicated by viral load, lung inflammation, clinical outcome and reduction of lethality. The protection induced by SpiN was ablated by depletion of CD4+ and CD8+ T cells and not transferred by antibodies from vaccinated mice. Finally, vaccination with SpiN also protects the K18-ACE-2 mice against infection with Delta and Omicron SARS-CoV-2 isolates. Hence, vaccine formulations that elicit effector T cells specific for the N and RBD proteins may be used to improve COVID-19 vaccines and potentially circumvent the immune escape by variants of concern.
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference73 articles.
1. Jeyanathan, M. et al. Immunological considerations for COVID-19 vaccine strategies. Nat. Rev. Immunol. 20, 615–632 (2020). 2. Dai, L. & Gao, G. F. Viral targets for vaccines against COVID-19. Nat. Rev. Immunol. 21, 73–82 (2021). 3. Berrio, A., Gartner, V. & Wray, G. A. Positive selection within the genomes of SARS-CoV-2 and other Coronaviruses independent of impact on protein function. PeerJ 8, e10234 (2020). 4. McCormick, K. D., Jacobs, J. L. & Mellors, J. W. The emerging plasticity of SARS-CoV-2. Science 371, 1306–1308 (2021). 5. Dejnirattisai, W. et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell 184, 2939–2954 e2939 (2021).
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|